Nanogen (NGEN) Awarded New CDC Contract to Develop Molecular Diagnostic Test for Influenza and Avian Flu
More News related to NGEN
- Nanogen (NGEN) Reports a Q3 Loss; FY Guidance Unchanged
- Nanogen (NGEN) and The Elitech Group Announce Merger Agreement
- Nanogen (NGEN) Reports Q2 Loss of $0.07
- Nanogen (NGEN) Awarded New CDC Contract to Develop Molecular Diagnostic Test for Influenza and Avian Flu
- Nanogen (NGEN) Announces Consolidation of Point of Care Manufacturing Operations
More News related to Corporate News
- Griffin (NYSE: GFF) Subsidiary Telephonics Awarded $6.9M Contract from Lockheed Martin (LMT) for Helicopter Support Systems
- New Jersey AG Approves Limited Use of Electronic Stun Guns (TASR)
- Salix Pharma (SLXP) Completes 5.5M Common Offering at $21/Share
- Highlights From LDK's Q3 Conference Call: Sales up 23% Over Prior Quarter; Guides Well Above for Q4
- Highlights From JOBS Q3 Conference Call: Shares Jump on Strong Earnings and Rebound in Market Demand
Nanogen (Nasdaq: NGEN) announced it has been awarded a new $10.4 million, two-year contract from the U.S. Centers for Disease Control and Prevention (CDC) to develop a multi-analyte molecular diagnostic assay for Influenza. This new contract will have Nanogen develop a fast molecular test that simultaneously detects and differentiates Influenza Type A, Influenza Type B, seasonal flu (H1N1 and H3N2) strains, and Respiratory Syncytial Virus (RSV). The contract provides for a secondary, "reflex", test for avian flu strains (H5N1, H7N1, and H9N1) to be available for samples that are determined to be positive for Flu A but negative for seasonal flu. RSV is the most common cause of bronchiolitis and pneumonia among infants and children under one year of age.
Related Categories
Corporate NewsFDA
Stocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
